Abstract
Current progress in the nuclear medicine field has been exploited in the design of tumour-targeting nanoscale carriers being able to deliver radionuclides in a selective manner to improve the outcome of both cancer diagnosis and therapy. In this field dendrimers have a role to play, thanks to their controlled architecture allowing multivalent attachment possibilities of radionuclide chelators and targeting moieties. This perspective highlights the current research focused on discrete dendritic systems as nanoprobes for nuclear medical imaging, both for Single Photon Emission Computed Tomography (SPECT) (99mTc, 111In, 125I) and Positron Emission Tomography (PET) (68Ga). Also a special emphasis is given on radiolabeled (64Cu, 18F, 76Br, 68Ga, 111In) dendrimers targeting αvβ3 integrin as it is a reliable strategy to assess the presence of angiogenesis, one of the most studied and also targeted biological processes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
